Stock Groups

Lantheus Holdings Earnings and Revenue Beat Pushes Shares 32% Higher -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Lantheus Holdings Inc (NASDAQ:) reported its fourth-quarter and full-year results for 2021, resulting in its shares rallying 32.54% on Thursday.

Revenues of the developer and manufacturer diagnostic imaging products topped analysts’ estimates of $111.78 millions.

Analysts had predicted earnings per share of 16 cents, but 25 cents was a better result. After launching PYLARIFY (a PSMA PET imaging agent to treat prostate cancer), full-year earnings beat expectations. 

Mary Anne Heino (President and CEO at Lantheus) stated that “Lantheus delivered another solid quarter and full-year, highlighted by revenue performances which increased 38% & 25% respectively.” 

She added that “We will keep pushing our goal to find, fight and follow serious medical conditions in 2022 to improve patient outcomes and drive shareholder value and revenue growth.”

The FDA approved the on-site facility for manufacturing, which was a strong start to 2022. 

Lantheus expects to generate revenue between $160 and $170 millions in the first quarter. 

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]